Niagen Bioscience Reports $6.3 Million Net Income and $31.5 Million in Sales for Q1 2026

Niagen Bioscience, Inc. reported a net income of $6.3 million for the first quarter of 2026, an increase from $5.1 million in the same period of 2025. This translates to a basic income per share of $0.08, up from $0.07 year-over-year. The company's total net sales reached $31.5 million, reflecting a 3% increase from $30.5 million in the prior year. The growth in revenue was primarily driven by the consumer products and ingredients segments, which saw increases of 4% and 5%, respectively. The consumer products segment, which includes the flagship product Tru Niagen®, contributed $22.4 million to net sales, while the ingredients segment generated $8.6 million.

In terms of operational changes, Niagen Bioscience completed the sale of its analytical reference standards and services segment in February 2026 for approximately $6 million. This divestiture resulted in a gain of $4.8 million, which was recognized in the current quarter's financial results. The company anticipates that this strategic move will allow it to focus more on its core offerings and improve its overall financial performance. Following the sale, the revenue from the analytical segment is no longer included in ongoing operations, which is expected to streamline the company's revenue mix towards higher-growth areas.

The company also reported significant changes in its balance sheet, with total assets increasing to $114.3 million as of March 31, 2026, compared to $106.4 million at the end of 2025. Current assets rose to $105.1 million, driven by increases in cash and cash equivalents, trade receivables, and inventory. However, current liabilities also increased to $23 million, up from $19.9 million, primarily due to higher accounts payable and accrued expenses. The company's stockholders' equity improved to $82.3 million, reflecting a reduction in the accumulated deficit from $164.5 million to $158.2 million.

Operationally, Niagen Bioscience has seen fluctuations in customer engagement metrics. The company reported a decrease in sales to its major customer, A.S. Watson, which fell by $2.4 million compared to the previous year, attributed to variability in ordering patterns. However, the company has been actively working on marketing initiatives to enhance its relationship with this partner. Additionally, the company has been focusing on expanding its e-commerce channels, which have shown promising growth, contributing to the overall increase in consumer product sales.

Looking ahead, Niagen Bioscience remains optimistic about its growth trajectory, supported by its strong cash position of $66.5 million and ongoing investments in research and development. The company plans to continue leveraging its proprietary ingredient technologies and expanding its product offerings, including a new topical skincare product. While the company expects some fluctuations in cash flows due to changes in operating results and inventory management, it believes that its current financial resources will be sufficient to meet its obligations over the next twelve months.